Security key
603170101
Mineralys Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MLYS)
CUSIP: 603170101
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 117,708
- Total 13F value
- $3,177,335
- Share change
- -117,567
- SEC-reported price per share
- $26.98
- Number of holders
- 7
- Value change
- -$3,186,780
- Number of buys
- 3
- Number of sells
- 2
- Shares outstanding
- 79,235,030
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
7
Top holders
7
MLYS full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
Mineralys Therapeutics, Inc. SEC filings
Mineralys Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 603170101
Recent filing periods:
Ownership snapshot
Top reported holders of MLYS - Mineralys Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Catalys Pacific Fund, LP
Disclosed value leader
Catalys Pacific Fund, LP
Comparable rows
15/15
Latest evidence
31 Mar 2026
13D/G
13F
3/4/5
Lead comparable stake: 10%
13D/G row: Catalys Pacific Fund, LP
Showing 1-6 of 15 holder rows.
Quick read
Catalys Pacific Fund, LP leads the comparable SEC ownership view at 10%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Catalys Pacific Fund, LP's linked filing trail.
Comparable ownership
Top 5
Catalys Pacific Fund, LP
10%
RA CAPITAL MANAGEMENT, L.P.
9.9%
Samsara BioCapital, L.P.
8.2%
FMR LLC
6.3%
BlackRock, Inc.
5.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Catalys Pacific Fund, LP |
13D/G
|
10%
|
$267,051,367
8,002,738 shares
|
-$32,576,328 | 31 Dec 2025 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
13D/G
3/4/5
Company · Director
|
9.9%
from 13D/G
|
$208,396,598
7,692,750 shares
|
— | 31 Mar 2026 |
| Samsara BioCapital, L.P. |
13D/G
Srinivas Akkaraju
|
8.2%
|
$85,419,771
6,346,194 shares
|
+$8,209,106 | 04 Sep 2025 |
| FMR LLC |
13D/G
13F
Company
|
6.3%
|
$182,087,409
5,017,509 shares
|
$0 | 31 Dec 2025 |
| BlackRock, Inc. |
13D/G
13F
Company
|
5.2%
|
$149,286,258
4,113,657 shares
|
$0 | 31 Dec 2025 |
| Andera Partners |
13F
13D/G
Company
|
4.2%
from 13D/G
|
$43,125,032
1,591,917 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
7
Shares
117,708
Rows available
7
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
213
Q2 2026 holders
7
Holder diff
-206
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend